Drug Etiology of Aplastic Anemia and Related Dyscrasias

This study has been completed.
Sponsor:
Information provided by:
National Heart, Lung, and Blood Institute (NHLBI)
ClinicalTrials.gov Identifier:
NCT00005302
First received: May 25, 2000
Last updated: June 23, 2005
Last verified: May 2000
  Purpose

To determine the role of drugs in the etiology of aplastic anemia, agranulocytosis, and thrombocytopenic purpura. Drugs used in chemotherapy and immunotherapy were excluded.


Condition
Blood Disease
Anemia, Aplastic
Agranulocytosis
Purpura, Thrombocytopenic

Study Type: Observational

Resource links provided by NLM:


Further study details as provided by National Heart, Lung, and Blood Institute (NHLBI):

Study Start Date: April 1985
Estimated Study Completion Date: June 1992
Detailed Description:

BACKGROUND:

It was well established that drugs played a role in the etiology of aplastic anemia, agranulocytosis, and thrombocytopenic purpura. In 1985, much of the evidence concerning the relation of exposure to drugs to the risk of the three dyscrasias was based on case reports. Such reports could sometimes be appropriate for raising hypotheses, but they rarely served to establish associations firmly. They could also be subject to selection bias due to a tendency to publish reports only when a dyscrasia followed the use of a drug already under suspicion, and could result in spurious and non-causal associations. Moreover, since denominator populations were not known, case reports could never provide quantitative estimates of associations, either in terms of their magnitude or of the incidence rates attributable to the specific exposures The sparse quantitative information that did exist was of variable quality because of methodological and other difficulties. And while overall incidence rates, within orders of magnitude, could be estimated for the three dyscrasias, there was virtually no acceptably reliable information available on the incidence rates due to specific drugs. Even for well known associations such as aplastic anemia with chloramphenicol, estimates of incidence, if given at all, were imprecise.

The list of drugs incriminated at one time or another in the etiology of each dyscrasia was as long as the pharmacopoeia itself. Based on the clinical evidence, however, there were patterns for each dyscrasia, some of which overlapped. Drugs commonly linked to aplastic anemia included chloramphenicol, phenylbutazone, oxyphenbutazone, sulfonamides, and antithyroid drugs; all of them, except chloramphenicol, were also implicated in the etiology of agranulocytosis, together with phenothiazine derivatives. The same drugs were commonly linked to thrombocytopenia, which had also frequently been linked to the use of quinidine. The exact listing of drugs related to each disorder varied between reports and, presumably, between patterns of drug use in different populations. One major concern in 1985 was with all of the newer nonsteroidal anti-inflammatory drugs currently on the market in the United States. There were numerous case reports implicating these drugs in the etiology of all three dyscrasias.

DESIGN NARRATIVE:

The design was that of a case-control study. All hospitals with at least 100 beds in geographically defined areas of eastern Massachusetts and Rhode Island were enrolled. All cases of aplastic anemia and agranulocytosis were identified prospectively for the purpose of estimating incidence rates. A proportion of cases of thrombocytopenic purpura were identified but incidence rates were not estimated. The eligibility of cases was determined by a committee of hematologists, according to strict diagnostic criteria. All identified cases of the dyscrasias, suitable hospital controls, and, in Massachusetts, neighbor controls were interviewed. Information was obtained on drug use, occupational and chemical exposure, personal data, and relevant medical history. The data were used to quantify known associations between the three dyscrasias and drug use, to identify and quantify previously unsuspected associations, and to document absence of associations for commonly used drugs. Incidence rates of aplastic anemia and agranulocytosis attributable to specific drugs and classes of drugs were estimated.

  Eligibility

Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

Publications:
ClinicalTrials.gov Identifier: NCT00005302     History of Changes
Other Study ID Numbers: 3003
Study First Received: May 25, 2000
Last Updated: June 23, 2005
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Agranulocytosis
Anemia
Anemia, Aplastic
Hematologic Diseases
Purpura
Purpura, Thrombocytopenic
Leukopenia
Leukocyte Disorders
Bone Marrow Diseases
Blood Coagulation Disorders
Hemorrhage
Pathologic Processes
Skin Manifestations
Signs and Symptoms
Thrombotic Microangiopathies
Thrombocytopenia
Blood Platelet Disorders
Immune System Diseases

ClinicalTrials.gov processed this record on July 24, 2014